One of our favorite pancreatic cancer researchers, Dr. Daniel Von Hoff of TGen in Arizona – together with researchers from the Virginia G Piper Cancer Center – is reporting encouraging clinical trials results for those with advanced pancreatic cancer (ductal adenocarcinoma of the pancreas) treated with a combination of Abraxane plus gemcitabine. This MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study as chaired by Dr. Von Hoff is a part of a multi-center international investigation of 861 pancreatic cancer patients with results that are expected to be reported out in greater detail at the ASCO GI symposium in San Francisco. Dr. Von Hoff was a key researcher on the early development of gemcitabine.
Dale O’Brien, MD